In this episode, we discuss the surge in popularity of edibles containing minor cannabinoids in the market. Recent data from BayMedica shows a 47 percent year-over-year growth, reaching $391 million in sales. Minor cannabinoids like CBC, THCV, CBDV, and CBN offer unique therapeutic benefits, leading to a 6.3 percent higher average item price for brands incorporating them. The future of edibles lies in strategically integrating these minor cannabinoids to meet evolving consumer needs for holistic well-being.